Latest news with #Ethicon
7NEWS
01-05-2025
- Health
- 7NEWS
Women left waiting for share of $405m mesh implant payout
More than 1000 women injured from defective pelvic mesh implants await assessment for compensation, two years after mammoth settlements were reached. Meant to assist women with prolapses and leakage, the flawed products routinely caused chronic pain, incontinence, and pain during sexual intercourse. Device makers Johnson and Johnson, Ethicon and Boston Scientific agreed to pay $405 million in compensation in settlements approved by the Federal Court in late 2022 and early 2023. But the court was told on Thursday 1020 women were yet to be assessed for compensation two years on. Blame has been laid on difficulties obtaining the medical records necessary to complete the assessments. 'An enormous amount of work has been done, but there are stragglers,' the administrators' lawyer Guy Donnellan told the court on Thursday. Medical records for the women assessed come from various practices and are not connected to doctors who administered the vaginal mesh and tape implants, the court was told. Since the settlements, just $25 million has been paid out to more than 6000 women deemed eligible by administrators, Donnellan told Justice Michael Lee. Women who receive this first interim payment will be eligible for further compensation in future. About 15,000 women who received implants from Ethicon have been assessed with 1000 remaining, while some 20 of the 2698 women who received Boston Scientific implants were still waiting. A small group of women have been deemed ineligible for compensation, he said. Thursday's hearing came on International Mesh Awareness Day, recognising women and some men who were affected by the implants across decades. Hundreds of South Australians injured by the implants were issued with a formal government apology on Wednesday night. 'I am sorry for the pain, embarrassment, and gaslighting you have endured,' Health Minister Chris Picton said. 'For the times you questioned your own experiences and were dismissed by those who were meant to care for you.' Picton said the government would continue to educate doctors and improve services for those seeking care to ensure it would not happen again. The compensation pool is being administered by a trio of firms — BDO, JGA Saddler and Slater and Gordon. Shine Lawyers ran the class actions, understood at the time to be the largest ever legal win of its type, but were prevented from managing the settlement distribution scheme. When appointed in 2023, the settlement firms said they expected it could take 30 to 36 months to complete.
Perth Now
01-05-2025
- Health
- Perth Now
Women left waiting for share of $405m implant payout
More than 1000 women injured from defective pelvic mesh implants await assessment for compensation, two years after mammoth settlements were reached. Meant to assist women with prolapses and leakage, the flawed products routinely caused chronic pain, incontinence, and pain during sexual intercourse. Device makers Johnson & Johnson, Ethicon and Boston Scientific agreed to pay $405 million in compensation in settlements approved by the Federal Court in late 2022 and early 2023. But the court was told on Thursday 1020 women were yet to be assessed for compensation two years on. Blame has been laid on difficulties obtaining the medical records necessary to complete the assessments. "An enormous amount of work has been done, but there are stragglers," the administrators' lawyer Guy Donnellan told the court on Thursday. Medical records for the women assessed come from various practices and are not connected to doctors who administered the vaginal mesh and tape implants, the court was told. Since the settlements, just $25 million has been paid out to more than 6000 women deemed eligible by administrators, Mr Donnellan told Justice Michael Lee. Women who receive this first interim payment will be eligible for further compensation in future. About 15,000 women who received implants from Ethicon have been assessed with 1000 remaining, while some 20 of the 2698 women who received Boston Scientific implants were still waiting. A small group of women have been deemed ineligible for compensation, he said. Thursday's hearing incidentally came on International Mesh Awareness Day, recognising women and some men who were affected by the implants across decades. Hundreds of South Australians injured by the implants were issued with a formal government apology on Wednesday night. "I am sorry for the pain, embarrassment, and gaslighting you have endured," Health Minister Chris Picton said. "For the times you questioned your own experiences and were dismissed by those who were meant to care for you." Mr Picton said the government would continue to educate doctors and improve services for those seeking care to ensure it would not happen again. The compensation pool is being administered by a trio of firms - BDO, JGA Saddler and Slater and Gordon. Shine Lawyers ran the class actions, understood at the time to be the largest ever legal win of its type, but were prevented from managing the settlement distribution scheme. When appointed in 2023, the settlement firms said they expected it could take 30 to 36 months to complete.
Yahoo
31-01-2025
- Business
- Yahoo
Hemostatic Wound Dressing Markets, 2023-2024 & Forecast to 2030 - Growing Demand from Healthcare and Military Sectors Fuels Expansion
Global Hemostatic Wound Dressing Market Dublin, Jan. 31, 2025 (GLOBE NEWSWIRE) -- The "Hemostatic Wound Dressing Market by Type, by Application, by End-user, and by Region" report has been added to global hemostatic wound dressing market accounted for USD 0.464 billion in 2023 and is expected to reach USD 1.35 billion by 2034 with a CAGR of 10.17% during the forecast period 2024-2034 The market will grow as a result of rising surgical procedures, advancements in hemostatic technologies, an increase in the incidence of chronic diseases, growing demand from the military and defense sector, government initiatives and the development of healthcare infrastructure, and rising awareness of hemostatic products. Innovations that increase market appeal and promote adoption include the use of bioactive compounds, synthetic polymers, and nanotechnology. Market expansion is driven by growing patient and healthcare professional knowledge of hemostatic wound dressings' advantages in minimizing complications, lowering blood loss, and improving patient outcomes. Campaigns for education and training initiatives increase awareness and uptake even further. For instance, Ethicon announced in October 2023 the release of their SURGIFLO Hemostatic Matrix with HALT Hemostasis, a next-generation hemostatic matrix intended to stop bleeding quickly and sustainably during surgery. North American region is anticipated to have the highest revenue share during the forecast period owing to the well-established healthcare infrastructure, high adoption rate of advanced medical technologies, increasing prevalence of chronic diseases requiring surgical interventions, and strong presence of key market players driving innovation and market penetration. Additionally, the Asia Pacific region is estimated to grow at the fastest CAGR during the forecast period owing to the rapidly expanding healthcare infrastructure, growing investments in medical research and development, rising prevalence of chronic diseases, increasing geriatric population, and improving accessibility to healthcare services. For instance, BD introduced Arista AH, an absorbable surgical hemostatic powder made from pure plant starch, in June 2023. According to the manufacturer, this will serve as an additional hemostatic tool to help when ligatures, pressure, and other traditional methods of controlling capillary, venous, and arteriolar bleeding prove to be inefficient or unworkable. By type, the thrombin-based hemostats segment accounted for the highest revenue-grossing segment in the global hemostatic wound dressing market in 2023 owing to the advanced hemostatic properties of thrombin and its widespread usage in surgical procedures, trauma management, and emergency settings. For instance, Baxter announced in January 2024 that it was purchasing PerClot, a powdered hemostatic agent, from CryoLife Inc. to increase the range of sophisticated hemostats and sealants that it offers. Additionally, the combination hemostats segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing demand for versatile hemostatic solutions combining the benefits of multiple materials, such as natural and synthetic agents, to effectively control bleeding in diverse clinical application, the trauma segment accounted for the highest revenue-grossing segment in the global hemostatic wound dressing market in 2023 owing to the rising incidence of traumatic injuries, accidents, and emergencies necessitating immediate and effective hemostatic intervention to control bleeding and prevent further complications. For instance, Integra LifeSciences reported in December 2023 that the FDA had cleared their DuraGen Plus Dural Regeneration Matrix, which is utilized in neurosurgery procedures to support and provide a barrier for dural healing. Additionally, the general surgery segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing number of general surgical procedures globally, driving the demand for hemostatic wound dressings to ensure efficient bleeding control and better patient end-user, the hospitals segment accounted for the highest revenue-grossing segment in the global hemostatic wound dressing market in 2023 owing to the prevalence of surgical procedures and trauma cases, leading to a higher demand for hemostatic wound dressings in hospital settings where immediate and effective bleeding control is critical for patient care. For instance, Teleflex announced in February 2024 the release of their Hemostatic Matrix with Rapid Thrombus Formation Technology, which is intended to effectively control bleeding during a variety of surgical procedures. Additionally, the ambulatory surgical centers segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing preference for outpatient surgical procedures, advancements in medical technology allowing for more complex surgeries in ambulatory settings, and the emphasis on cost-effective healthcare Scope: Base Year: 2023 Forecast Period: 2024-2034 Study Coverage Market Forecast by Type, Application, and End-User Market Forecast for 5 Regions and 17+ Countries North America (U.S. and Canada) Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe) Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC) Latin America (Brazil, Mexico, Argentina, Rest of LATAM) MEA (South Africa, GCC, Rest of MEA) Exhaustive Company Profiles of the Top 10+ Major Market Players 20% Free Customization Available to Meet Your Exact Requirement Key Attributes: Report Attribute Details No. of Pages 200 Forecast Period 2023 - 2034 Estimated Market Value (USD) in 2023 $0.46 Billion Forecasted Market Value (USD) by 2034 $1.35 Billion Compound Annual Growth Rate 10.1% Regions Covered Global Companies Featured Ethicon Baxter International Inc. CR Bard (acquired by BD) B. Braun Melsungen AG Pfizer Inc. Integra LifeSciences Corporation Marine Polymer Technologies Inc. Z-Medica LLC Teleflex Incorporated CryoLife Inc. Hemostasis LLC Cohera Medical Inc. Arch Therapeutics Inc. Biom'up SA Celox Medical. Hemostatic Wound Dressing Market Analysis & Forecast by Type 2023 - 2034 (Revenue USD Bn) Thrombin based Hemostats Gelatin Hemostats Combination Hemostats Collagen-based Hemostats Oxidized Regenerated Cellulose Hemostats Hemostatic Wound Dressing Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn) Trauma Cardiovascular Surgery General Surgery Plastic Surgery Orthopedic Surgery Neurosurgery Hemostatic Wound Dressing Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Bn) Hospitals Ambulatory Surgical Centers Tactical Combat Casualty Care Centers Hemostatic Wound Dressing Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn) North America U.S. Canada Europe Germany France UK Spain Italy Rest of Europe Asia Pacific China Japan India Australia South Korea Rest of APAC Latin America Brazil Mexico Argentina Rest of LATAM Middle East & Africa South Africa GCC Rest of MEA For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Global Hemostatic Wound Dressing Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
